- Home
- DXLG vs ALGS Comparison
DXLG vs ALGS Comparison
Compare DXLG & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- ALGS
- Stock Information
- Founded
- DXLG 1976
- ALGS 2018
- Country
- DXLG United States
- ALGS United States
- Employees
- DXLG N/A
- ALGS N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- DXLG Consumer Discretionary
- ALGS Health Care
- Exchange
- DXLG Nasdaq
- ALGS Nasdaq
- Market Cap
- DXLG 55.4M
- ALGS 64.8M
- IPO Year
- DXLG 1987
- ALGS 2020
- Fundamental
- Price
- DXLG $0.91
- ALGS $6.56
- Analyst Decision
- DXLG Strong Buy
- ALGS Strong Buy
- Analyst Count
- DXLG 1
- ALGS 2
- Target Price
- DXLG $2.50
- ALGS $60.00
- AVG Volume (30 Days)
- DXLG 49.3K
- ALGS 78.4K
- Earning Date
- DXLG 12-04-2025
- ALGS 11-06-2025
- Dividend Yield
- DXLG N/A
- ALGS N/A
- EPS Growth
- DXLG N/A
- ALGS N/A
- EPS
- DXLG N/A
- ALGS N/A
- Revenue
- DXLG $447,744,000.00
- ALGS $2,646,000.00
- Revenue This Year
- DXLG N/A
- ALGS N/A
- Revenue Next Year
- DXLG $3.95
- ALGS N/A
- P/E Ratio
- DXLG N/A
- ALGS N/A
- Revenue Growth
- DXLG N/A
- ALGS N/A
- 52 Week Low
- DXLG $0.89
- ALGS $3.76
- 52 Week High
- DXLG $3.10
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- DXLG 35.07
- ALGS 32.95
- Support Level
- DXLG $0.89
- ALGS $6.10
- Resistance Level
- DXLG $1.00
- ALGS $7.00
- Average True Range (ATR)
- DXLG 0.06
- ALGS 0.74
- MACD
- DXLG 0.00
- ALGS -0.16
- Stochastic Oscillator
- DXLG 11.30
- ALGS 19.29
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.